Associated Papers
Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
Dougherty BA et al.
Oncotarget, 2017
28525389 (PubMed )
Supplement: oncotarget-08-43653-s002.docx
Select a paper to view details